Estrogen and Coronary Heart Disease in Women

JAMA: The Journal of the American Medical Association

Volumn 265, Issue 14, 1991, Pages 1861-1867

  Barrett Connor, Elizabeth ^a   Bush, Trudy L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; HUMAN; MENOPAUSE; PRIORITY JOURNAL;

AGE FACTORS; CONTRACEPTIVES, ORAL, HORMONAL; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMAN; MENOPAUSE; MENSTRUATION; PARITY; RISK FACTORS; SEX FACTORS;

EID: 0025755590     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1991.03460140089033     Document Type: Article

References (91)

1. Glendy RE, Levine SA, White PD. Coronary disease in youth: comparison of 100 patients under 40 with 300 persons past 80. JAMA. 1937;109:1775-1778.
2. Stamler J, Pick R, Katz LN. Experiences in assessing estrogen antiatherogenesis in the chick, the rabbit, and man. Ann N Y Acad Sci. 1956; 64:596-619.
3. Stamler J, Pick R, Katz LN. Prevention of coronary atherosclerosis by estrogen-androgen administration in the cholesterol-fed chick. Circ Res. 1953;1:94-98.
4. Vermeulen A. Androgen secretion after age 50 in both sexes. Horm Res. 1983;18:37-42.
5. Tikkanen MJ, Nikkilä EA, Kuusi T, Sipinen S. High density lipoprotein2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metabol. 1982;54:1113-1117.
6. Tikkanen MJ, Kuusi T, Nikkilä EA, Stenman UH. Variation of postheparin plasma hepatic lipase by menstrual cycle. Metabolism. 1986;35:99-104.
7. Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman’s lifetime. Am J Obstet Gynecol. 1988;158:1630-1643.
8. Lipid Research Clinics Population Studies Data Book: The Prevalence Study. Bethesda, Md: US Dept of Health and Human Services; 1980;1. NIH publication 80-1527.
9. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641-646.
10. Winkelstein W, Stenchever MA, Lilienfeld AM. Occurrence of pregnancy, abortion, and artificial menopause among women with coronary artery disease: a preliminary study. J Chronic Dis. 1958;7:273-286.
11. Winkelstein W, Rekate AC. Age trend of mortality from coronary artery disease in women and observations on the reproductive patterns of those affected. Am Heart J. 1964;67:481-488.
12. Parrish HM, Carr CA, Silberg SL, King TM. Relationship of pregnancy to coronary artherosclerosis. Am J Obstet Gynecol. 1967;97:1087-1091.
13. Bengtsson C, Rybo G, Westerberg H. Number of pregnancies, use of oral contraceptives and menopausal age in women with ischaemic heart disease, compared to a population sample of women. Acta Med Scand. 1973;549(suppl):75-81.
14. Talbott EO, Kuller LH, Perper J, Murphy P. Sudden unexpected death in women. Am J Epidemiol. 1981;114:672-682.
15. Beard CM, Fuster V, Annegers JF. Reproductive history in women with coronary heart disease: a case-control study. Am J Epidemiol. 1984; 120:108-114.
16. Beral V. Long-term effects of childbearing on health. J Epidemiol Community Health. 1985; 39:343-346.
17. Beard CM, Griffith M, Offord K, Edwards WD. Risk factors for sudden unexpected cardiac death in young women in Rochester, Minnesota. 1960-1974. Mayo Clin Proc. 1986;61:186-191.
18. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. A prospective study of age at menarche, parity, age at first birth, and coronary heart disease in women. Am J Epidemiol. 1987;126:861-870.
19. LaVecchia C, Decarli A, Franceschi S, Gentile A, Negri E, Parazzini F. Menstrual and reproductive factors and risk of myocardial infarction in women under 55 years of age. Am J Obstet Gynecol. 1987;157:1108-1112.
20. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ Oral Contraception Study. BMJ. 1989;298:165-168.
21. Talbott EO, Kuller LH, Detre K, et al. Reproductive history of women dying of sudden cardiac death: a case-control study. Int J Epidemiol. 1989;18:589-594.
22. Royal College of General Practitioners’ Oral Contraception Study: further analyses of mortality in oral contraceptive users. Lancet. 1981;1:541-546.
23. Hubert HB, Eaker ED, Garrison RJ, Castelli WP. Life-style correlates of risk factor change in young adults: an eight-year study of coronary heart disease risk factors in the Framingham offspring. Am J Epidemiol. 1987;125:812-831.
24. Kritz-Silverstein D, Barrett-Connor E, Wingard DL. The relation between reproductive history and lipid levels in older women. Circulation. 1990;81:718.
25. Adams MR, Kaplan JR, Clarkson TB, Koritnik DR. Endogenous sex steroids and coronary artery atherosclerosis in cynomolgus macaques. In: Gallo OL, ed. Cardiovascular Disease: Molecular and Cellular Mechanisms: Prevention and Treatment. New York, NY: Plenum Press; 1987:381-387.
26. Wuest JH, Dry TJ, Edwards JE. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation. 1953;7:801-808.
27. Rivin AU, Dimitroff SP. The incidence and severity of atherosclerosis in estrogen-treated males, and in females with a hypoestrogenic or a hyperestrogenic state. Circulation. 1954;9: 533-539.
28. Oliver MF, Boyd GS. Effect of bilateral ovariectomy on coronary-artery disease and serum-lipid levels. Lancet. 1959;2:690-694.
29. Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch Intern Med. 1959;104:908-913.
30. Novak ER, Williams TJ. Autopsy comparison of cardiovascular changes in castrated and normal women. Am J Obstet Gynecol. 1966;80:863-872.
31. Ask-Upmark E. Life and death without ovaries. Acta Med Scand. 1962;172:129-135.
32. Ritterband AB, Jaffe IA, Densen PM, Magagna JF, Reed E. Gonadal function and the development of coronary heart disease. Circulation. 1963;26:237-251.
33. Sznajderman M, Oliver MF. Spontaneous premature menopause, ischaemic heart-disease, and serum-lipids. Lancet. 1963;1:962-965.
34. Oliver MF. Ischaemic heart disease in young women. BMJ. 1974;4:253-259.
35. Mann JI, Inman WHW. Oral contraceptives and death from myocardial infarction. BMJ. 1975;2:245-248.
36. Johansson BW, Kaij L, Kullander S, Lenner H-C, Svanberg L, Astedt B. On some late effects of bilateral oophorectomy in the age range 15-30 years. Acta Obstet Gynecol Scand. 1975;54: 449-461.
37. Kannel WB, Hjortland M, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976;85:447-552.
38. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
39. Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D. Mortality among oral contraceptive users: 20-year follow up of women in a cohort study. BMJ. 1989;299:1487-1491.
40. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319:1313-1317.
41. Kay C. The Royal College of General Practitioners’ Oral Contraception Study: some recent observations. Clin Obstet Gynecol. 1984;11:759-786.
42. Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med. 1981;305:612-618, 672-677.
43. Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. BMJ. 1975;2:241-245.
44. Mann JI, Inman WHW, Thorogood M. Oral contraceptive use in older women and fatal myocardial infarction. BMJ. 1976;2:445-447.
45. Shapiro S, Slone D, Rosenberg L, Kaufman DW, Stolley PD, Miettinen OS. Oral-contraceptive use in relation to myocardial infarction. Lancet. 1979;1:743-747.
46. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA. 1979;242:1150-1154.
47. Rosenberg L, Hennekens CH, Rosner B, Belanger C, Rothman KJ, Speizer FE. Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol. 1980;111:59-66.
48. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med. 1981; 305:420-424.
49. Sullivan JM, Zwaag RV, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 1988;108:358-363.
50. Gruchow HW, Anderson AJ, Barboriak JJ, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 1988;115:954-963.
51. McFarland KF, Boniface ME, Hormung CA, et al. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J. 1989;117:1209-1214.
52. Lafferty FW, Helmuth DO. Post-menopausal estrogen replacement: the prevention of osteoporosis and systemic effects. Maturitas. 1985;7:47-59.
53. Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med. 1985;313:1044-1049.
54. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy, II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74-79.
55. Hammond CB, Jelovsek FR, Lee KL, et al. Effects of long-term estrogen replacement therapy, I: metabolic effects. Am J Obstet Gynecol. 1979;133:525-536.
56. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and non-contraceptive estrogen use in women: results from the Lipid Research Clinics’ Program Follow-Up Study. Circulation. 1987;75:1002-1009.
57. Talbott E, Kuller LH, Detre K, et al. Biologic and psychosocial risk factors of sudden death from coronary disease in white women. Am J Cardiol. 1977;39:858-864.
58. Rosenberg L, Armstrong B, Jick H, et al. Myocardial infarction and estrogen therapy in postmenopausal women. N Engl J Med. 1976;294:1256-1259.
59. Henderson BE, Paganini-Hill A, Ross RK. Estrogen replacement therapy and protection from acute myocardial infarction. Am J Obstet Gynecol. 1988;159:312-317.
60. Beard CM, Kottke TE, Annegers JF, et al. The Rochester Coronary Heart Disease Project: effect of cigarette smoking, hypertension, diabetes, and steroidal estrogen use on coronary heart disease among 40- to 59-year old women, 1960 through 1982. Mayo Clin Proc. 1989;64:1471-1480.
61. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-terfollow-wup of women in the Walnut Creek study. Obstet Gynecol. 1987;70:289-293.
62. Avila MH, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1990;1:128-135.
63. Adam S, Williams V, Vessey MP. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. BMJ. 1981;282:1277-1278.
64. Szklo M, Tonascia J, Gordis L, et al. Estrogen use and myocardial infarction risk: a case-control study. Prev Med. 1984;13:510-516.
65. Rosenberg L, Slone D, Shapiro S, et al. Non-contraceptive estrogens and myocardial infarction in young women. JAMA. 1980;244:339-342.
66. Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health. 1989;43:173-178.
67. LaVecchia C, Franceschi S, Decarli AS, et al. Risk factors for myocardial infarction in young women. Am J Epidemiol. 1987;125:832-843
68. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use and heart disease. N Engl J Med. 1986;315:135.
69. Jick H, Dinan B, Rothman KJ. Noncontraceptive estrogens and nonfatal myocardial infarction. JAMA. 1978;239:1407-1409.
70. Eaker ED, Castelli WP. Differential risk for coronary heart disease among women in the Framingham Study. In: Eaker E, Packard B, Wenger N, Clarkson T, Tyroler HA, eds. Coronary Heart Disease in Women. New York, NY: Haymarket Doyma; 1987:122-130.
71. Burch JC, Byrd BF Jr, Vaughn WK. The effects of long-term estrogen on hysterectomized women. Am J Obstet Gynecol. 1974;118:778-782.
72. MacMahon B. Cardiovascular disease and non-contraceptive oestrogen therapy. In: Oliver MF, ed. Coronary Heart Disease in Young Women. Edinburgh, Scotland: Churchill Livingstone Publisher; 1978.
73. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol. 1987;94:620-635.
74. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors in the 1980s. JAMA. 1989;261:2095-2100.
75. Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol. 1989;161:1854-1858.
76. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 1980;303:1038-1041.
77. Bush TL, Barrett-Connor E. Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev. 1985;7:80-104.
78. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell DR, ed. Menopause: Physiology and Pharmacology. Chicago, Ill: Year Book Medical Publishers Inc; 1987:187-208.
79. Barrett-Connor E. Putative complications of estrogen replacement therapy: hypertension, diabetes, thrombophlebitis, and gallstones. In: Korenman SG, ed. The Menopause. Norwell, Mass: Serono Symposia; 1990:199-209.
80. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins, and coronary heart disease in women. Clin Chem. 1988;34:B60-B70.
81. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis. July/August 1990;10:531-534.
82. Steinleitner A, Stanczyk FZ, Levin JH, et al. Decreased in vitro production of 6-keto-prostaglandin by uterine arteries from postmenopausal women. Am J Obstet Gynecol. 1989;161:1677-1681.
83. Abraham GE, Maroulis GB. Effect of exogenous estrogen on serum pregnenolone, cortisol, and androgens in postmenopausal women. Obstet Gynecol. 1975;45:271-274.
84. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986; 74:758-765.
85. Lippman ME, Bates S, Huff KK, et al. Estrogens regulate production of specific growth factors in hormone-dependent human breast cancer. J Lab Clin Med. 1987;109:230-235.
86. Harder DR, Coulson PB. Estrogen receptors and effects of estrogen on membrane electrical properties of coronary vascular smooth muscle. J Cell Physiol. 1979;100:375-382.
87. McGill HC. Sex steroid hormone receptors in the cardiovascular system. Postgrad Med. April 1989:64-68.
88. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 1990;81:1680-1687.
89. Barrett-Connor E. Postmenopausal estrogen, cancer and other considerations. Women Health. Fall/Winter 1986;11:179-195.
90. Henderson BE, Ross RK, Paganini-Hill A, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol. 1986;154:1181-1186.
91. Ernster VL, Bush TL, Huggins GR, Hulka BS, Kelsey JL, Schottenfeld D. Clinical perspectives: benefits and risks of menopausal estrogen and/or progestin hormone use. Prev Med. 1988;17: 201-223.